title: [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
abstract: Ten children were treated with recombinant human tissue plasminogen activator (rh-tPA) for severe hepatic veno-occlusive disease (VOD) that developed after bone marrow transplantation. Treatment with rh-tPA was begun a median of 22 days (range; 13-127 days) after transplantation. Seven of 9 (78%) evaluable patients had complete resolution of their VOD. Four patients had hemorrhagic complications, and 2 of them died because of pulmonary hemorrhage and subdural hemorrhage, respectively. Although rh-tPA seems to be an effective therapy for established VOD, further studies will be necessary to determine its safety as well as the optimal dosing regimen.
authors.affiliation: Division of Hematology and Oncology, Japanese Red Cross Nagoya First Hospital.
authors.forename: A
authors.initials: A
authors.lastname: Yoshimi
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: N
authors.initials: N
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Matsuyama
authors.forename: S
authors.initials: S
authors.lastname: Kojima
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006408:Hematoma, Subdural / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D008171:Lung Diseases / Q000175:diagnosis; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator